Europe’s first allogeneic stem cell therapy rejected by NICE
Cost regulators for the NHS in England and Wales have not approved funding for TiGenix and Takeda’s Alofisel – the first allogeneic stem cell therapy to be approved for use across the European Union – for use in Crohn’s patients in draft guidelines.
Read More





